化学
重编程
细胞毒性T细胞
免疫系统
T细胞
细胞生物学
CD8型
细胞
颗粒酶
颗粒酶B
红细胞
癌症研究
颗粒酶A
转录组
细胞膜
巨噬细胞
下调和上调
分子生物学
血细胞
调节器
调节性T细胞
癌细胞
免疫
生物
癌症免疫疗法
作者
Xinxin Zhang,Zheng Xiang,Wei Wang,Haikun Cao,Hui Song,Wenlong You,Changqian Guo,Anqi Wang,Bo Zhang,Jianguang Jia
摘要
ABSTRACT Engineered biomimetic nanovesicle systems represent an emerging strategy for targeted immune modulation in cancer. In this study, we developed anti‐CD8a‐functionalized red blood cell membrane–derived nanovesicles (NVE) to selectively deliver the NFAT5 inhibitor KRN2 to CD8 + T cells. Transcriptomic and single‐cell RNA sequencing analyses identified NFAT5 as a transcriptional regulator associated with PD‐1 expression in highly exhausted CD8 + T cell subsets in cardia cancer. CD8a‐NVE@KRN2 showed favourable physicochemical properties, efficient KRN2 loading, and preferential CD8 + T cell targeting. Functionally, targeted NFAT5 inhibition restored CD8 + T cell activity, promoted granzyme A–gasdermin B‐mediated tumour cell pyroptosis, and indirectly shifted tumour‐associated macrophages toward a more inflammatory, glycolysis‐associated phenotype. In subcutaneous and orthotopic models, CD8a‐NVE@KRN2 enhanced the antitumour effect of anti‐PD‐1 therapy. These findings support functionalized red blood cell membrane nanovesicles as a biomimetic platform for coordinated immune reprogramming in cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI